The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

CHICAGO -- An investigational allogeneic stem cell-derived islet-cell therapy helped almost all patients with type 1 diabetes achieve insulin independence within the year, a small phase I/II study ...

A retrospective study assessed infusion with axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel from 2018 to 2023 to examine cytokine release syndrome and immune effector ...

A substantial proportion of patients with autoimmune diseases experienced a new side effect called local immune effector cell–associated toxicity syndromes (LICATS) after receiving chimeric antigen ...

A recent study published in Nature Immunology demostrates that durable asthma remission can be achieved with engineered and long-lived chimeric antigen receptor (CAR) T-cell treatment in mice. Study: ...

Share on Pinterest A new study found that CAR T-cell therapy may help people with glioblastoma. Cavan Images/Getty Images Recurrent glioblastoma, the most aggressive form of brain tumor, has no ...

Please provide your email address to receive an email when new articles are posted on . Two first-in-class adoptive cell therapies show promise for patients with advanced melanoma or synovial sarcoma.

Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimislecel ...